PRESS RELEASE: Vita 34 AG launches a voluntary public exchange offer on PBKM shares

DGAP-News: Vita 34 AG / Keyword (s): Miscellaneous Vita 34 AG launches a voluntary public exchange offer on PBKM shares 2021-09-20 / 08:00 The issuer is solely responsible for the content of this announcement.

————————————————– ————————————————– ——————-

NOT FOR DISTRIBUTION, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION OR TO DO SO CONSTITUTE A VIOLATION OF APPLICABLE LAWS OR REGULATIONS Vita 34 voluntarily launches exchange offer on PBKM shares. Vita 34 has published the prospectus for a voluntary public exchange offer for shares of Polski Bank KomórekMacierzystych SA (“PBKM”). . As of today, PBKM shareholders can tender their PBKM shares for Vita 34 shares at an exchange ratio of 1.3 new Vita 34 shares in exchange for one (1) PBKM share. Leipzig / Warsaw, September 20, 2021 – Following the approval of the securities prospectus by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) and the notification of the prospectus to the Polish Financial Supervisory Authority (Komisja Nadzoru Finansowego), Vita 34 AG (“Vita 34”, ISIN: DE000A0BL849; WKN: A0BL84), Leipzig, announces the start of the acceptance period of the voluntary exchange offer (“Exchange Offer”) for all the outstanding shares of Polski Bank Komórek Macierzystych SA, Warsaw (“PBKM”, ISIN: PLPBKM000012; WKN: A2AJKP). As previously announced, Vita 34 is offering 1.3 new Vita 34 shares in exchange for each PBKM share. The Exchange Offer is, among other things, subject to a minimum acceptance threshold of 95%. The detailed terms and conditions of the Exchange Offer can be found in the prospectus, which was published today on the Internet at: (by accessing (“Investor Relations” (“Share” (“PBKM Exchange Offer”). The acceptance period begins today, September 20, 2021, and is expected to end on October 18, 2021 at 24: 00 CEST Vita 34 and PBKM The Boards of Directors support the business combination of the two companies on the basis of the long-term accretive value creation potential for both groups of shareholders 34 shares (equivalent to approximately 68, 14% of the current share capital of PBKM.) These shareholders include (among others) AOC Health GmbH, Jakub Baran, Chairman of the Board of PBKM, and Tomasz Baran, Vice Chairman of the Board of PBKM. Dr. Wolfgang Knirsch, CEO of Vita 34 AG: “We encourage the shareholders of PBKM to accept our offer, as the business combination has a convincing strategic rationale, bringing together highly complementary companies and creations. The first pan-European cord blood bank fami lial. The strong support for this combination from over two-thirds of PBKM shareholders underscores the expectation that Vita 34 and PBKM together can create greater shareholder value in the future. Jakub Baran, co-founder, shareholder and chairman of the board of directors of PBKM said: “In my opinion, the exchange parity offered by Vita 34 benefits the shareholders of PBKM. What makes it even more appealing is that after the exchange of PBKM shares for Vita 34 shares, current PBKM shareholders will own shares of the largest entity with a market capitalization of almost 250 million. euros, greater liquidity and listed on the Frankfurt Stock Exchange. Exchange – one of the main European exchanges. I would also like to add that I have already made a commitment to exchange the PBKM shares that I hold for the shares of Vita 34. I think our minority shareholders see the upcoming business combination as the next important step for the further dynamic development of the Famicord. . Group and they will participate in the share exchange transaction. ”Important information This announcement does not constitute an offer to exchange or purchase or the solicitation of an offer to exchange or purchase securities. the solicitation of an offer to purchase securities in PBKM or Vita 34. The final conditions and other provisions concerning the exchange offer are published in the securities prospectus, the publication of which has been authorized by the Federal Authority German Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) Investors and holders of PBKM shares are strongly recommended to read the prospectus and all other documents relating to the Exchange Offer as soon as they are published, as they will contain Important information Subject to the exceptions described in the securities prospectus and any exceptions granted by the relevant regulatory authorities, an exchange offer is not applicable. aite, directly or indirectly, in or to jurisdictions where it would constitute a violation under the laws of those jurisdictions. In particular, the Exchange Offer is not made and the Vita 34 shares which are intended to be transferred to the shareholders of PBKM in return (the “Vita 34 Offered Shares”) cannot be offered, sold or delivered, directly. or indirectly, in or in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia) (“United States”), Australia, Canada, Japan or South Africa. The Vita 34 Offering Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”), or under any securities laws of any country. United States state, district or other jurisdiction. States. About Vita 34 Vita 34 was founded in 1997 in Leipzig and today is one of the leading cell banks in Europe. As the first private cord blood bank in Europe and a pioneer in cell banking, the company has since offered collection logistics, processing and storage of blood stem cells and umbilical cord tissues as a service provider complete for cryopreservation. Based on the expansion of the business model in 2019, Vita 34 also intends to offer storage of immune cells from peripheral blood and stem cells from autologous fat in the future. Endogenous cells are a valuable starting material for medical cell therapy and are kept alive at temperatures of around minus 200 degrees Celsius so they can be used as part of treatment if needed. More than 247,000 customers from more than 20 countries have already ensured the health of their families with a cell deposit at Vita 34. For more information: About PBKM Polski Bank Komórek Macierzystych heads the international FamiCord group, which operates stem cell banks located in Europe. The FamiCord group stores 610,000 samples belonging to more than 450,000 families. FamiCord’s main activity is the supply, processing and long-term storage of stem cells from umbilical cord blood and other post-fetal tissues on behalf of parents (family banking). The purpose of this bank is to ensure the safety of the family in the event of serious illness requiring a stem cell transplant in the donor or members of his immediate family. The FamiCord Group is now present in more than 35 European countries. It provides services directly to clients in Poland, Turkey, Spain, Portugal, Hungary, Romania, Switzerland, Italy, Luxembourg, Germany, Latvia, Lithuania and Estonia, and more recently in the Czech Republic, Slovakia, Great Britain, Middle Orient (Dubai, Abu Dhabi, Lebanon) and Hong Kong. It is one of the leading companies in almost all of these countries. In addition, it provides services to partners who acquire customers in Sweden, Denmark, Serbia and the Balkan countries, Italy and Ukraine. The Group’s services are provided through a network of its own banks and cooperating banks located in Switzerland, Sweden, Ukraine, the United States and other countries. In addition, the Group invests in the development of manufacturing services for advanced therapy drugs (ATMP), considered to be one of the most important developments in medicine. The PBKM group is also involved in nearly 10 clinical trials, in which drugs based on stem cell fractions have already been administered to patients about 700 times. Since May 2016, PBKM has been listed on the main market of the Warsaw Stock Exchange. For more information:,, Twitter @PBKM_FamiCord Contact Investor Relations Vita 34: Ingo Middelmenne, Middelmenne & Cie., Tel +49 (0) 341 48792-40, Email: [email protected] Press contact Vita 34: Peter Steiner, Jan P. Sefrin, Charles Barker Corporate Communications, Tel. : +49 69 794 090 27, E-mail [email protected] PBKM media contact: Michal Wierzchowski, cc group, Tel. : +48 531 613 067, E-mail [email protected]

————————————————– ————————————————– ——————-

2021-09-20 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this advertisement. DGAP’s distribution services include regulatory announcements, financial / corporate news, and press releases. Archives on

————————————————– ————————————————– ——————-

Language:     English 
Company:      Vita 34 AG 
              Deutscher Platz 5a 
              04103 Leipzig 
Phone:        +49(0341)48792-40 
Fax:          +49(0341)48792-39 
E-mail:       [email protected] 
ISIN:         DE000A0BL849 
WKN:          A0BL84 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1234379 
End of News   DGAP News Service 

1234379 2021-09-20

(MORE FOLLOWING) Dow Jones Newswires

September 20, 2021 02:00 ET (06:00 GMT)

Source link

About Carrie Scheer

Check Also

Elon Musk arrives as Tesla opens German ‘gigafactory’ to the public

After Tesla founder Elon Musk proposed to build the electric carmaker’s first European “gigausine” in …

Leave a Reply

Your email address will not be published. Required fields are marked *